Emerging treatment strategies and potential therapeutic targets in primary Sjögren's syndrome

Inflammation and Allergy - Drug Targets

Volumn 9, Issue 1, 2010, Pages 10-19

  Becker, Heidemarie ^a   Pavenstaedt, Hermann ^a   Willeke, Peter ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Adaptive immunity; B lymphocyte; Cytokines; Innate immunity; Sicca syndrome; Sj gren's syndrome

Indexed keywords

ATACICEPT; AZATHIOPRINE; B CELL ACTIVATING FACTOR; CHEMOKINE; CYCLOSPORIN A; EFALIZUMAB; EPRATUZUMAB; ETANERCEPT; FINGOLIMOD; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 23; MACROPHAGE MIGRATION INHIBITION FACTOR; METHOTREXATE; MIZORIBINE; MYCOPHENOLIC ACID; NATALIZUMAB; PRASTERONE; REBAMIPIDE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; THALIDOMIDE; TOLL LIKE RECEPTOR; UNINDEXED DRUG;

ACINAR CELL; ADAPTIVE IMMUNITY; ALLOGENEIC STEM CELL TRANSPLANTATION; APOPTOSIS; B LYMPHOCYTE; CELL REGENERATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EXOCRINE SECRETION; EYE SURGERY; GENETIC POLYMORPHISM; HUMAN; HYPERGAMMAGLOBULINEMIA; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; LACRIMAL DUCT; LYMPHOCYTE MIGRATION; LYMPHOCYTIC INFILTRATION; ORTHOSTATIC HYPOTENSION; PALLIATIVE THERAPY; PAROTITIS; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN EXPRESSION; PSORIASIS; PUNCTAL PLUG; QUALITY OF LIFE; RASH; REGULATORY T LYMPHOCYTE; REVIEW; SEDATION; SIDE EFFECT; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; VASCULITIS;

EID: 77949394094     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152810791292935     Document Type: Review

References (110)

1. Kassan, S.S.; Moutsopoulos, H.M. Clinical manifestations and early diagnosis of Sjögren's syndrome. Arch. Intern. Med., 2004, 164, 1275-84.
2. Manoussakis, M.N.; Moutsopoulos, H.M. Sjögren's syndrome: current concepts. Adv. Intern. Med., 2001, 47, 191-217.
3. Theander, E.; Henriksson, G.; Ljungberg, O.; Mandl, T.; Manthorpe, R.; Jacobsson, L.T. Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann. Rheum. Dis., 2006, 65, 796-803.
4. Zintzaras E.; Voulgarelis, M.; Moutsopopulos, H.M. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch. Intern. Med., 2006, 165, 2337-44.
5. Vitali, C.; Bombardieri, S.; Jonsson, R.; Moutsopoulos, H.M.; Alexander, E.L.; Carsons, S.E.; Daniels, T.E.; Fox, P.C.; Fox, R.L.; Kassan S.S.; Pillemer, S.R.; Talal, N.; Weisman, M.H. European study group on classification criteria for Sjögren's syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis., 2002, 61, 554-8.
6. Hansen, A.; Lipsky, P.E.; Dörner, T. Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy. Curr. Opin. Rheumatol., 2005, 17, 558-65.
7. Jonsson, M.V.; Skarstein, K. Follicular dendritic cells confirm lymphoid organization in the minor salivary glands of primary Sjögren's syndrome. J. Oral Pathol. Med., 2008, 37, 515-21.
8. Mitsias, D.I.; Kapsogeorgou, E.K.; Moutsopoulos, H.M. Sjögren's syndrome: why autoimmune epithelitis? Oral Dis., 2006, 12, 523-32.
9. Bertorello, R.; Cordone, M.P.; Contini, P.; Rossi, P.; Indiveri, F.; Puppo, F.; Cordone, G. Increased levels of interleukin-10 in saliva of Sjögren's syndrome patients: correlation with disease activity. Clin. Exp. Med., 2004, 4, 148-51.
10. Bombardieri, M.; Barone, F.; Pittoni, V.; Alessandri, C.; Conigliaro, P.; Blades, M.C.; Priori, R.; McInnes, I.B.; Valesini, G.; Pitzalis, C. Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjögren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate. Arthritis Res. Ther., 2004, 6, R447-456.
11. Nordmark, G.; Alm, G.V.; Ronnblom, L. Mechanisms of disease: primary Sjogren's syndrome and the type I interferon system. Nat. Clin. Pract. Rheumatol., 2006, 2, 262-9.
12. Willeke, P.; Schotte, H.; Schlüter, B.; Erren, M.; Becker, H.; Dyong, A.;, Mickholz, E.; Domschke, W.; Gaubitz, M. Interleukin 1 beta and tumour necrosis factor alpha secreting cells are increased in the peripheral blood of patients with Sjögren's syndrome. Ann. Rheum. Dis., 2003, 62, 359-62.
13. Willeke, P.; Schlüter, B.; Schotte, H.; Domschke, W.; Gaubitz, M.; Becker, H. Interferon-gamma is increased in patients with primary Sjogren's syndrome and Raynaud's phenomenon. Seminars Arthritis Rheum., 2008, June 24 [Epub ahead of print].
14. Miyazaki, T.; Takeda, N.; Ishimaru, N.; Omotehara, F.; Arakaki, R.; Hayashi, Y. Analysis of in vivo role of alpha-fodrin autoantigen in primary Sjogren's syndrome. Am. J. Pathol., 2005, 167, 1051-9.
15. Mackay, F.; Groom, J.R.; Tangye, S.G. An important role for Bcell activation factor and B cells in the pathogenesis of Sjögren's syndrome. Curr. Opin. Rheumatol., 2007, 19, 406-13.
16. Mavragani, C.P.; Moutsopoulos, N.M.; Moutsopoulos, H.M. The management of Sjögren's syndrome. Nat. Clin. Pract. Rheumatol., 2006, 2, 252-61.
17. Nakayamada, S.; Saito, K.; Umehara, H.; Ogawa, N.; Sumida, T.; Ito, S.; Minota, S.; Nara, H.; Kondo, H.; Okada, J.; Mimori, T.; Yoshifuji, H.; Sano, H.; Hashimoto, N.; Sugai, S.; Tanaka, Y. Efficacy and safety of mizoribine for the treatment of Sjögren's syndrome: a multicenter open-label clinical trial. Mod. Rheumatol., 2007, 17, 464-9.
18. Willeke, P.; Schlüter, B.; Becker, H.; Schotte, H.; Domschke, W.; Gaubitz, M. Mycophenolate sodium treatment in patients with primary Sjögren's syndrome- a pilot trial. Arthritis Res. Ther., 2007, 9, R115
19. Berdoulay, A.; English, R.V.; Nadelstein, B. Effect of topical 0,02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca. Vet. Ophthalmol., 2005, 8, 225-32.
20. Avisar, R.; Savir, H.; Machtey, I.; Ovaknin, L.; Shaked, P.; Menache, R.; Allalouf, D. Clinical trial of bromhexine in Sjögren's syndrome. Ann. Ophthalmol., 1981, 13, 971-3.
21. Walters, M.T.; Rubin, C.E.; Keightley, S.J.; Ward, C.D.; Cawley, M.I. A double-blind, cross-over, study of oral N-acetylcyteine in Sjögren's syndrome. Scand. J. Rheumatol., 1986, 61(Suppl.), 253-8.
22. Jorkjend, L.; Bergenholtz, A.; Johansson, A.K.; Johansson, A. Effect of pilocarpine on impaired salivary secretion in patients with Sjögren's syndrome. Swed. Dent. J., 2008, 32, 49-56.
23. Ono, M.; Takamura, E.; Shinozaki, K.; Tsumura, T.; Hamano, T.; Yaki, Y.; Tsubota, K. Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomised, double-blind clinical study. Am. J. Ophthalmol., 2004, 138, 6-17.
24. Kasama, T.; Shiozawa, F.; Isozaki, T.; Matsunawa, M. Wakabayashi, K.; Odai, T.; Yajima, N.; Miwa, Y.; Negishi, M.; Ide, H. Effect of the H2 receptor antagonist nizatidine on xerostomia in patients with primary Sjögren's syndrome. Mod. Rheumatol., 2008, 18, 455-9.
25. Fox, P.C.; Datiles, M.; Atkinson, J.C.; Macynski, A.A.; Scott, J.; Fletcher, D.; Valdez, I.H.; Kurrasch, R.H.; Delapenha, R.; Jackson, W. Prednisone and piroxicam for treatment of primary Sjögren's syndrome. Clin.Exp.Rheumatol., 1993, 11, 149-56.
26. Miyawaki, S.; Nishiyama, S.; Matoba, K. Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjögren's syndrome. Intern. Med., 1999, 38, 938-43.
27. Leung, K.C.; McMillan, A.S.; Cheung, B.P.; Leung, W.K. Sjögren's syndrome sufferers have increased oral yeast levels despite regular dental care. Oral Dis., 2008, 14, 163-73.
28. Fox, R.I.; Dixon, R.; Guarrasi, V.; Krubel, S. Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus, 1996, 5(Suppl.1), S31-36.
29. Kruize, A.A.; Hené, R.J.; Kallenberg, C.G.; van Bijsterveld, O.P.; van der Heide, A.; Kater, L.; Bijlsma, J.W. Hydroxychloroquine treatment for primary Sjögrens's syndrome: a two year double blind crossover trial. Ann. Rheum. Dis., 1993, 52, 360-4.
30. Tishler, M.; Yaron, I.; Shirazi, I.; Yaron, M. Hydroxychloroquine treatment for primary Sjögrens's syndrome: its effect on salivary and serum inflammatory markers. Ann. Rheum. Dis., 1999, 58, 253-6.
31. Rihl, M.; Ulbricht, K.; Schmidt, R.E.; Witte, T. Treatment of sicca symptoms with hydroxychloroquine in patients with Sjögren's syndrome. Rheumatology, 2009, 48, 796-9.
32. de Seze, J.; Delalande, S.; Fauchais, A.L.; Hachulla, E.; Stojkovic, T.; Ferriby, D.; Hatron, P.Y.; Vermersch, P. Myelopathies secondary to Sjögren's syndrome: treatment with monthly intravenous cyclophosphamide associated with corticosteroids. J. Rheumatol., 2006, 33, 709-11.
33. Kaufman, I.; Schwartz, D.; Caspi, D.; Paran, D. Sjögren's syndrome - not just Sicca: renal involvement in Sjögren's syndrome. Scand. J. Rheumatol., 2008, 37, 213-8.
34. Takahashi, Y.; Takata, T.; Hoshino, M.; Sakurai, M.; Kanazawa, I. Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjögren's syndrome. IV immunoglobulin. Neurology, 2003, 60, 503-5.
35. Skopouli, F.N.; Jagiello, P.; Tsifetaki, N.; Moutsopoulos, H.M. Methotrexate in primary Sjögren's syndrome. Clin. Exp. Rheumatol., 1996, 14, 555-8.
36. Drosos, A.A.; Skopouli, F.N.; Costopoulos, J.S.; Papadimitriou, C.S.; Moutsopoulos, H.M. Cyclosporin A (CyA) in primary Sjögren's syndrome: a double blind study. Ann. Rheum. Dis., 1986, 45, 732-5.
37. Price, E.J.; Rigby, S.P.; Clancy, U.; Venables, P.J. A double blind placebo controlled trial in azathioprine in the treatment of primary Sjögren's syndrome. J. Rheumatol., 1998, 25, 896-9.
38. Van Woerkom, J.M.; Kruize, A.A.; Geenen, R.; van Roon, E.N.; Goldschmeding, R.; Verstappen, S.M.; van Roon, J.A.; Bijlsma, J.W. Safety and efficacy of leflunomide in primary Sjögrens's syndrome: a phase II pilot study. Ann. Rheum. Dis., 2007, 66, 1026-32.
39. Moutsopoulos, H.M.; Fragoulis, G.E. Is mizoribine a new therapeutic agent for Sjögren's syndrome? Nat. Clin. Prac. Rheumatol., 2008, 4, 350-1.
40. Dass, S.; Bowman, S.J.; Vital, E.M.; Ikeda, K.; Pease, C.T.; Hamburger, J.; Richards, A.; Rauz, S.; Emery, P. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomized, double-blind, placebo-controlled pilot trial. Ann. Rheum. Dis., 2008, 67, 1541-4.
41. Isaksen, K.; Jonssen, R.; Omdal, R. Anti-CD20 treatment in primary Sjögren's syndrome. Scand. J. Immunol., 2008, 68, 554-64.
42. Steinfeld, S.D.; Tant, L.; Burmester, G.R.; Teoh, N.K.; Wegener, W.A.; Goldenberg, D.M.; Pradier, O. Epratuzumab (humanized anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res. Ther., 2006, 8, R129.
43. Mackay, F.; Schneider, P.; Rennert, P.; Browning, J.L. BAFF and APRIL: a tutorial on B cell survival. Ann. Rev. Immunol., 2003, 21, 231-64.
44. Lavie, F.; Miceli-Richard, C.; Quillard, J.; Roux, S. ; Leclerc, P. ; Mariette, X. Expression of BAFF (BLys) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome. J. Pathol., 2004, 202, 496-502.
45. Lavie, F.; Miceli-Richard, C.; Ittah, M.; Sellam, J.; Gottenberg, J.E.; Mariette, X. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren's syndrome. Scand. J. Immunol., 2008, 67, 185-92.
46. Groom, J.; Kalled S.L.; Cutler, A.H; Olson, C.; Woodcock, S.A.; Schneider, P.; Tschopp, J.; Cachero, T.G.; Batten, M.; Wheway, J.; Mauri, D.; Cavill, D.; Gordon, T.P., Macakay, C.R.; Mackay, F. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J. Clin. Invest., 2002, 109, 59-68.
47. Mariette, X.; Roux, S. Zhang, J.; Benqoufa, D.; Lavie, F.; Zhou, T.; Kimberly, R. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann. Rheum. Dis., 2003, 62, 168-71.
48. Lavie, F.; Miceli-Richard, C.; Ittah, M.; Sellam, J.; Gottenberg, J.E.; Mariette, X. Increase of B cell activating factor of the TNF family (BAFF) after rituximab: insights into a new regulating system of BAFF production. Ann. Rheum. Dis., 2007, 66, 700-3.
49. Quartuccio, L.; Fabris, M.; Moretti, M.; Barone, F.; Bombardieri, M.; Rupolo, M.; Lombardi, S.; Pitzali, C., Beltrami, C.A.; Curcio, F.; de Vita, S. Resistence to rituximab therapy and local BAFF overexpression in Sjögren's syndrome- related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma. Open Rheumatol. J., 2008, 2, 38-43.
50. Baker, K.P.; Edwards, B.M.; Main, S.H.; Choi, G.H.; Wager, R.E.; Halpern, W.G.; Lappin, P.B.; Riccobene, T.; Abramian, D.; Sekut, L.; Sturm, B.; Poortman, C.; Minter, R.R.; Dobson, C.L.; Williams, E.; Carmen, S.; Smith, R.; Roschke, V.; Hilbert, D.M.; Vaughan, T.J.; Albert, V.R. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum., 2003, 48, 3253-65.
51. Dall'Era, M.; Chakravarty, E.; Wallace, D.; Genovese, M.; Weisman, M.; Kavanaugh, A.; Kalunian, K.; Dhar, P.; Vincent, E.; Pena-Rossi, C.; Wofsy, D.; and the Merck Serono and ZymoGenetics Atacicept Study Group. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus. Arthritis Rheum., 2007, 56, 4142-50.
52. Tak, P.P.; Thurlings, R.M.; Rossier, C.; Nestorov, I.; Dimic, A.; Mircetic, V.; Rischmueller, M.; Nasonov, E.; Shmidt, E.; Emery, P.; Munafo, A. Atacicept in patients with rheumatoid arthritis. Arthritis Rheum., 2008, 58, 61-72.
53. Shen, L.; Suresh, L.; Li, H.; Zhang, C.; Kumar, V.; Pankewycz, O.; Ambrus, J.L.Jr. IL-14 alpha, the nexus for primary Sjögren's disease in mice and humans. Clin. Immunol., 2009, 130, 304-12.
54. Mariette, X.; Ravaud, P.; Steinfeld, S.; Baron, G.; Goetz, J.; Hachulla, E., Combe, B.; Puéchal, X.; Pennec, Y.; Sauvezie, B.; Perdriger, A.; Hayem, G.; Janin, A.; Sibilia, J. Inefficacy of infliximab in primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum., 2004, 50, 1270-6.
55. Sankar, V.; Brennan, M.T.; Kok, M.R.; Leakan, R.A.; Smith, J.A.; Manny, J.; Baum, B.J.; Pillemer, S.R. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum., 2004, 50, 2240-5.
56. Moutsopoulos, N.M.; Katsifis, G.E.; Angelov, N.; Leakan, R.A.; Sankar, V.; Pillemer, S.; Wahl, S.M. Lack of efficacy of etanercept in Sjögren's syndrome correlates with failed suppression of tumour necrosis factor α and systemic immune activation. Ann. Rheum. Dis., 2008, 67, 1437-43.
57. Mavragani, C., Niewold, T.B.; Moutsopoulos, N.M.; Pillemer, S.R.; Wahl, S.M., Crow, M.K. Exaggeration of Interferon-alpha pathway and BAFF production in patients with Sjögren's syndrome after anti-TNF treatment. Arthritis Rheum., 2007, 56, 3995-4004.
58. Moutsopoulos, N.M.; Angelov, N.; Sankar, V.; Leakan, R.A.; Pillemer, S.; Wahl, S.M. Immunological consequences of thalidomide treatment in Sjögren's syndrome. Ann. Rheum. Dis., 2006, 65, 112-4.
59. Manoussakis, M.N.; Boiu, S.; Korkolopoulou, P.; Kapsegeorgou, E.K.; Kavantzas, N.; Ziakas, P.; Patsouris, E.; Moutsopoulos, H.M. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjögren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum., 2007, 56, 3977-88.
60. McGrath-Morrow, S.; Laube, B.; Tzou, S.C.; Cho, C.; Cleary, J.; Kimura, H.; Rose, N.R.; Caturegli, P. IL-12 overexpression in mice as a model for Sjögren lung disease. Am. J. Physiol. Lung Cell. Mol. Physiol., 2006, 291, L837-46.
61. Kumar, H.; Kawai, T.; Akira, S. Pathogen recognition in the innate immune response. Biochem. J., 2009, 420, 1-16.
62. Kawakami, A.; Nakashima, K.; Tamai, M.; Nakamura, H.; Iwanaga, N.; Fujikawa, K.; Aramaki, T.; Arima, K.; Iwamoto, N.; Ichinose, K.; Kamachi, M.; Ida, H.; Origuchi, T.; Eguchi, K. Toll-like receptors in salivary glands from patients with Sjögren's syndrome: functional analysis by human salivary gland cell line. J. Rheumatol., 2007, 34, 1019-26.
63. Spachidou, M.P.; Bourazopoulou, E.; Maratheftis, C.L.; Kapsogeorgou, E.K.; Moutsopoulos, H.M.; Tzioufas, A.G.; Manoussakis, M.N. Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjogren's syndrome. Clin. Exp. Immunol., 2007, 147, 497-503.
64. Hoffman, H.M. Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS). Expert Opin. Biol. Ther., 2009, 9, 519-31.
65. Sacre, S.M.; Lo, A.; Gregory, B.; Simmonds, R.E., Williams, L.; Feldmann, M.; Brennan, F.M.; Foxwell, B.M. Inhibitors of TLR8 reduce TNF production from human rheumatoid synovial membrane cultures. J. Immunol., 2008, 181, 8002-9.
66. Stanczyk, J.; Ospelt, C.; Gay, S. Is there a future for small molecule drugs in the treatment of rheumatic diseases? Curr. Opin. Rheumatol., 2008, 20, 257-62.
67. Khoury, M.; Escriou, V.; Courties, G.; Galy, A.; Yao, R.; Largeau, C.; Scherman, D.; Jorgensen, C.; Apparailly, F. Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes. Arthritis Rheum., 2008, 58, 2356-67.
68. Steinman, R.M.; Hemmi, H. Dendritic cells: translating innate to adaptive immunity. Curr. Top. Microbiol. Immunol., 2006, 311, 17-58.
69. Gottenberg, J.E.; Cagnard, N.; Lucchesi, C.; Letourneur, F., Mistou, S.; Lazure, T.; Jacques, S., Ba, N. ; Ittah, M.; Lepajolec, C.; Labetoulle, M.; Ardizzone, M.; Sibilia, J.; Fournier, C.; Chiocchia, G.; Mariette, X. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc. Natl. Acad. Sci. USA, 2006, 103, 2770-5.
70. Wildenberg, M.E.; van Helden-Meeuwsen, C.G.; van de Merwe, J.P.; Drexhage, H.A.; Versnel, M.A. Systemic increase in type I interferon activity in Sjögren's syndrome: a putative role for plasmacytoid dendritic cells. Eur. J. Immunol., 2008, 38, 2024-33.
71. Wildenberg, M.E.; Welzen-Coppens, J.M.; van Helden-Meeuwsen, C.G.; Bootsma, H., Vissing, A.; van Rooijen, N.; van de Merwe, J.P.; Drexhage, H.A.; Versnel, M.A. Increased frequency of CD16+ monocytes and the presence of activated dendritic cells in salivary glands in primary Sjögren syndrome. Ann. Rheum. Dis., 2009, 68, 420-6.
72. Cummins, M.J.; Papas, A.; Kammer, G.M.; Fox, P.C. Treatment of primary Sjögren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum., 2003, 49, 585-93.
73. Bave, U.; Nordmark, G.; Lövgren, T.; Rönnelid, J.; Cajander, S.; Eloranta, M.L.; Alm, G.V.; Rönnblom, L. Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum., 2005, 52, 1185-95.
74. Willeke, P.; Gaubitz, M., Schotte, H.; Maaser, C.; Domschke, W.; Schlüter, B.; Becker, H. Increased serum levels of macrophage migration inhibitory factor in patients with primary Sjögren's syndrome. Arthritis Res. Ther., 2007, 9, R43.
75. Stavitsky, A.B.; Xianli, J. In vitro and in vivo regulation of macrophage migration inhibitory factor (MIF) of expression of MHC-II, costimulatory, adhesion, receptor, and cytokine molecules. Cell. Immunol., 2002, 217, 95-104.
76. Ayoub, S.; Hickey, M.J.; Morand, E.F. Mechanisms of disease: macrophage migration inhibitory factor in SLE, RA and atherosclerosis. Nat. Clin. Prac. Rheumatol., 2008, 4, 98-105.
77. Hoi, A.Y.; Iskander, M.N.; Morand, E.F. Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases. Inflamm. Allergy Drug Targets, 2007, 6, 183-90.
78. Mannon, P.J.; Fuss, I.J.; Mayer, L.; Elson, C.O.; Sandborn, W.J.; Present, D.; Dolin, B.; Goodman, N.; Groden, C.; Hornung, R.L.; Quezado, M.; Yang, Z.; Neurath, M.F.; Salfeld, J.; Veldman, G.M.; Schwertschlag, U.; Strober, W.; Anti-IL-12 Crohn's Disease Study Group. Anti interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med., 2004, 351, 2069-79.
79. Watfort, W.T.; Hissong, B.D.; Bream, J.H.; Kanno, Y.; Muul, L.; O'Shea, J.J. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol. Rev., 2004, 202, 139-59.
80. Romagnani, S. Human Th17 cells. Arthritis Res. Ther., 2008, 10, 206.
81. Nguyen, C.Q.; Hu, M.H.; Li, Y.; Stewart, C.; Peck, A.B. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjögren's syndrome: findings in human and mice. Arthritis Rheum., 2008, 58, 734-43.
82. Weber, J.; Keam, S.J. Ustekinumab. Bio.Drugs, 2009, 23, 53-61.
83. Akira, S. The role of IL-18 in innate immunity. Curr. Opin. Immunol., 2000, 12, 59-63.
84. Ogawa, N.; Ping, L.; Zhenjun, L.; Takada, Y.; Sugai, S. Involvement of the interferon-gamma-induced T cell-attracting chemokines, interferon-gamma- inducible 10-kd protein (CXCL10) and monokine induced by interferon gamma (CXCL9), in the salivary gland lesions of patients with Sjögren's syndrome. Arthritis Rheum., 2002, 46, 2730-41.
85. Hasegawa, H.; Inoue, A.; Kohno, M.; Muraoka, M.; Miyazaki, T.; Terada, M.; Nakayama, T.; Yoshie, O.; Nose, M.; Yasukawa, M. Antagonist of interferon-inducible protein 10/CXCL10 ameliorates the progression of autoimmune sialadenitis in MRL/lpr mice. Arthritis Rheum., 2006, 54, 1174-83.
86. Aziz, K.E.; McCluskey, P.J.; Montanaro, A.; Wakefield, D. Vascular endothelium and lymphocyte adhesion molecules in minor salivary glands of patients with Sjogren's syndrome. J. Clin. Lab. Immunol., 1992, 37, 39-49.
87. MacDonald, J.K.; McDonald, J.W.D. Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst. Rev., 2007, Issue 1. Art. No.: CD006097. DOI: 10.1002/14651858.CD006097. pub2.
88. Wenning; W.; Haghikia, A.; Laubenberger, J.; Clifford, D.B.; Behrens, P.F.; Chan, A.; Gold, R. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N. Engl. J. Med., 2009, 361, 1075-80.
89. Li, X.; Li., X.; Qian, L.; Wang, G.; Zhang, H.; Wang, X.; Chen, K.; Zhai, Z.; Li, Q.; Wang, Y.; Harris, D.C. T regulatory cells are markedly diminished in diseased salivary glands of patients with primary Sjögren's syndrome. J. Rheumatol., 2007, 34, 2438-45.
90. Daniel, C.; Sartory, N.; Zahn, N.; Geisslinger, G.; Radeke, H.H.; Stein, J.M. FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. J. Immunol., 2007, 178, 2458-68.
91. Sekiguchi, M.; Iwasaki, T.; Kitano, M.; Kuno, H.; Hashimoto, N.; Kawahito, Y.; Azuma, M.; Hla, T.; Sano, H. Role of sphingosine 1-phosphate in the pathogenesis of Sjögren's syndrome. J. Immunol., 2008, 180, 1921-8.
92. O'Connor, P.; Comi, G.; Montalban, X.; Antel, J.; Radue, E.W.; de Vera, A.; Pohlmann, H.; Kappos, L.; FTY720 D2201 Study group. Oral fingolimod (FTY720) in multiple sclerosis. Neurology, 2009, 6, 73-9.
93. Haneji, N.; Nakamura, T.; Takio, K.; Yanagi, K.; Higashiyama, H.; Saito, I.; Noji, S.; Sugino, H.; Hayashi, Y. Identification of alphafodrin as a candidate autoantigen in primary Sjögren's syndrome. Science, 1997, 276(5312), 604-607.
94. Manganelli, P.; Fietta, P. Apoptosis and Sjögren's syndrome. Semin. Arthritis Rheum., 2003, 33, 49-65.
95. Hayashi, Y.; Arakaki, R.; Ishimaru, N. The role of caspase cascade on the development of primary Sjögren's syndrome. J. Med. Invest., 2003, 50, 32-8.
96. Bulosan, M.; Pauley, K.M.; Yo, K.; Chan, E.K.; Katz, J.; Peck, A.B.; Cha, S. Inflammatory caspases are critical for enhanced cell death in the target tissue of Sjögren's syndrome before disease onset. Immunol. Cell. Biol., 2009, 87, 81-90.
97. Sugai, S.; Takahashi, H.; Ohta, S.; Nishinarita, M.; Takei, M.; Sawada, S.; Yamaji, K.; Oka, H.; Umehara, H.; Koni, I.; Sugiyama, E.; Nishiyama, S.; Kawakami, A. Efficacy and safety of rebamipide for the treatment of dry mouth symptoms in patients with Sjögren's syndrome: a double-blind placebo-controlled multicenter trial. Mod. Rheumatol., 2009, 19, 114-24.
98. Kimura, T.; Fukui, H.; Sekikawa, A.; Yamagishi, H.; Ichikawa, K.; Tomita, S.; Fujii, S.; Imura, J.; Kawamata, H.; Chiba, T.; Imai, Y.; Fujimori, T. Involvement of REG I?? protein in the regeneration of ductal epithelial cells in the minor salivary glands of patients with Sjögren's syndrome. Clin. Exp. Immunol., 2009, 155, 16-20.
99. Hartkamp, A.; Geenen, R.; Godaert, G.L.; Bootsma, H.; Kruize, A.A.; Bijlsma, J.W.; Derksen, R.H. Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjögren syndrome: a randomised controlled trial. Ann. Rheum. Dis., 2008, 67, 91-7.
100. He, J.; Zhao, J.; Li, Z. Mucosal administration of alpha-fodrin inhibits experimental Sjögren's syndrome autoimmunity. Arthritis Res. Ther., 2008, 10, R44.
101. Kurien, B.T.; Asfa, S.; Li, C.; Dorri, Y.; Jonssen, R.; Scofield, R.H. Induction of oral tolerance in experimental Sjogren's syndrome autoimmunity. Scand. J. Immunol., 2005, 61, 418-25.
102. Lodde, B.M.; Mineshiba, F.; Wang, J.; Cotrim, A.P.; Afione, S.; Tak, P.P.; Baum, B.J. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome. Ann. Rheum. Dis., 2006, 65, 195-200.
103. Kagami, H.; Wang, S.; Hai, B. Restoring the function of salivary glands. Oral Dis., 2008, 14, 15-24.
104. Seror, R.; Ravaud, P.; Bowman, S.; Baron, G.; Tzioufas, A.; Theander, E.; Gottenberg, J.-E.; Bootsma, H.; Mariette, X.; Vitali, C. EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI): Development of a consensus systemic disease activity index in primary Sjögren's syndrome. Ann. Rheum. Dis., 2009, June 28 [Epub ahead of print].
105. Christodoulou, M.I.; Kapsogeorgou, E.K.; Moutsopoulos, N.M.; Moutsopoulos, H.M. Foxp3+ T-regulatory cells in Sjögren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors. Am. J. Pathol., 2008, 173, 1389-96.
106. Szodoray, P.; Alex, P.; Brun, J.G.; Centola, M.; Jonsson, R. Circulating cytokines in primary Sjögren's syndrome determined by a multiplex cytokine array system. Scand. J. Immunol., 2004, 59, 592-9.
107. Ulbricht, K.U.; Schmidt, R.E., Witte, T. Antibodies against alphafodrin in Sjögren's syndrome. Autoimmun. Rev., 2003, 2, 109-13.
108. Willeke, P.; Gaubitz, M.; Schotte, H.; Becker, H.; Mickholz, E.; Domschke, W.; Schlüter, B. Clinical and immunological characteristics of patients with Sjögren's syndrome in relation to α-fodrin antibodies. Rheumatology, 2007, 46, 479-83.
109. Willeke, P.; Gaubitz, M.; Schotte, H.; Becker, H.; Domschke, W.; Schlüter, B. The role of interleukin-10 promoter polymorphisms in primary Sjogren's syndrome. Scand. J. Rheumatol., 2008, 37, 293-9.
110. Pertovaara, M.; Antonen, J.; Hurme, M. Th2 cytokine genotypes are associated with a milder form of primary Sjögren's syndrome. Ann. Rheum.Dis., 2006, 65, 666-70.